Radioimmunotherapy for high-grade glioma

Immunotherapy

Volumn 5, Issue 6, 2013, Pages 647-659

  De Bonis, Pasquale ^a,b   Lofrese, Giorgio ^a   Anile, Carmelo ^a   Pompucci, Angelo ^a   Vigo, Vera ^a   Mangiola, Annunziato ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

EGF receptor; glioblastoma; high grade glioma; monoclonal antibody; radioimmunotherapy; radionuclides; tenascin C

Indexed keywords

81C6 MONOCLONAL ANTIBODY; COTARA; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETARACIZUMAB; ETARACIZUMAB Y 90; GA17 MONOCLONAL ANTIBODY IN 111; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 425 I 125; MU81C6 MONOCLONAL ANTIBODY I 131; MULTIDRUG RESISTANCE PROTEIN 3; NIMOTUZUMAB; NZ 1 MONOCLONAL ANTIBODY I 125; PENTETIC ACID; PODOPLANIN; PROTEOCHONDROITIN SULFATE; RADIOACTIVE IODINE; RADIOISOTOPE; RHENIUM 188; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TENASCIN; TENASCIN MONOCLONAL ANTIBODY; TETRAXETAN; UNCLASSIFIED DRUG; YTTRIUM 90;

APOPTOSIS; BLOOD BRAIN BARRIER; CANCER GRADING; CANCER PROGNOSIS; CELL CYCLE PROGRESSION; CLINICAL EFFECTIVENESS; COMPETITIVE INHIBITION; CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG UPTAKE; EXTRACELLULAR MATRIX; GAMMA RADIATION; GLIOBLASTOMA; GLIOMA; HUMAN; ISOTOPE LABELING; METASTASIS; MOLECULAR WEIGHT; MUTATIONAL ANALYSIS; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TARGET CELL DESTRUCTION; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 84878730174     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.43     Document Type: Review

References (91)

1. Reardon DA, Zalutsky MR, Bigner DD. Antitenascin C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. 7(5), 675-687 (2007).
2. Mangiola A, Anile C, Pompucci A, Capone G, Rigante L, De Bonis P. Glioblastoma therapy: going beyond Hercules columns. Expert Rev. Neurother. 10(4), 507-514 (2010).
3. Mangiola A, De Bonis P, Maira G et al. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 113(4), 841-846 (2008).
4. De Bonis P, Fiorentino A, Anile C et al. The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma. Clin. Neurol. Neurosurg. pii: S0303-8467(12)00469-6 (2012).
5. De Bonis P, Anile C, Pompucci A et al. The influence of surgery on recurrence pattern of glioblastoma. Clin. Neurol. Neurosurg. 115(1), 37-43 (2013).
6. Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J. Nucl. Med. 46(Suppl. 1), S151-S156 (2005).
7. Aarts F, Bleichrodt RP, Oyen WJ, Boerman OC. Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother. Radiopharm. 23(1), 92-107 (2008).
8. Zalutsky MR. Targeted radiotherapy of brain tumours. Br. J. Cancer 90(8), 1469-1473 (2004).
9. Order SE, Sleeper AM, Stillwagon GB, Klein TL, Leichner PK. Current status of radioimmunoglobulins in the treatment of human malignancy. Oncology (Williston Park) 3(5), 115-120; discussion 122, 129-130 (1989).
10. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24(5), 823-834 (2006).
11. Goetz C, Rachinger W, Poepperl G et al. Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. Acta Neurochir. Suppl. 88, 69-75 (2003).
12. Merlo A, Mueller-Brand J, Maecke HR. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir. Suppl. 88, 83-91 (2003).
13. Paganelli G, Bartolomei M, Grana C, Ferrari M, Rocca P, Chinol M. Radioimmunotherapy of brain tumor. Neurol. Res. 28(5), 518-522 (2006).
14. Chiocca EA. Monoclonal antibodies. J. Neurosurg. 113(2), 190; discussion 190-191 (2010).
15. Yao Z, Garmestani K, Wong KJ et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J. Nucl. Med. 42(10), 1538-1544 (2001).
16. Hens M, Vaidyanathan G, Welsh P, Zalutsky MR. Labeling internalizing anti epidermal growth factor receptor variant III monoclonal antibody with 177Lu: in vitro comparison of acyclic and macrocyclic ligands. Nucl. Med. Biol. 36(2), 117-128 (2009).
17. Moosmayer D, Berndorff D, Chang CH et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin. Cancer Res. 12(18), 5587-5595 (2006).
18. Carlsson J, Ren ZP, Wester K et al. Planning for intracavitary anti EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. J. Neurooncol. 77(1), 33-45 (2006).
19. Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Nucl. Med. Biol. 37(7), 741-750 (2010).
20. Milenic DE, Garmestani K, Chappell LL et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. 29(4), 431-442 (2002).
21. Zalutsky MR, Zhao XG, Alston KL, Bigner D. High-level production of a-particle-emitting 211At and preparation of 211At-labeled antibodies for clinical use. J. Nucl. Med. 42(10), 1508-1515 (2001).
22. Behrem S, Zarkovic K, Eskinja N, Jonjic N. Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma. Croat. Med. J. 46(3), 417-422 (2005).
23. Hau P, Kunz-Schughart LA, Rummele P et al. Tenascin-C protein is induced by transforming growth factor-b1 but does not correlate with time to tumor progression in high-grade gliomas. J. Neurooncol. 77(1), 1-7 (2006).
24. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH. Clinical impact and functional aspects of tenascin C expression during glioma progression. Int. J. Cancer 98(3), 362-369 (2002).
25. Zagzag D, Friedlander DR, Dosik J et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res. 56(1), 182-189 (1996).
26. Zagzag D, Friedlander DR, Miller DC et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res. 55(4), 907-914 (1995).
27. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98(11), 2430-2439 (2003).
28. Takahashi H, Herlyn D, Atkinson B et al. Radioimmunodetection of human glioma xenografts by monoclonal antibody to epidermal growth factor receptor. Cancer Res. 47(14), 3847-3850 (1987).
29. Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. 273(5), 2817-2822 (1998).
30. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. 273(1), 200-206 (1998).
31. Spaeth N, Wyss MT, Pahnke J et al. Radioimmunotherapy targeting the extradomain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19). Nucl. Med. Biol. 33(5), 661-666 (2006).
32. Veeravagu A, Liu Z, Niu G et al. Integrin avb3-targeted radioimmunotherapy of glioblastoma multiforme. Clin. Cancer Res. 14(22), 7330-7339 (2008).
33. Burke PA, Denardo SJ, Miers LA, Kukis DL, Denardo GL. Combined modality radioimmunotherapy. Promise and peril. Cancer 94(Suppl. 4), S1320-S1331 (2002).
34. Burke PA, Denardo SJ, Miers LA, Lamborn KR, Matzku S, Denardo GL. Cilengitide targeting of avb3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 62(15), 4263-4272 (2002).
35. Fu Y, Ponce ML, Thill M, Yuan P, Wang NS, Csaky KG. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest. Ophthalmol. Vis. Sci. 48(11), 5184-5190 (2007).
36. Dumoff KL, Chu CS, Harris EE et al. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod. Pathol. 19(5), 708-716 (2006).
37. Ito T, Ishii G, Nagai K et al. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 63(3), 418-424 (2009).
38. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M. Enhanced expression of Aggrus (T1a/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol. 26(4), 195-200 (2005).
39. Kato Y, Kaneko MK, Kuno A et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem. Biophys. Res. Commun. 349(4), 1301-1307 (2006).
40. Martin-Villar E, Megias D, Castel S, Yurrita MM, Vilaro S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial- mesenchymal transition. J. Cell Sci. 119(Pt 21), 4541-4553 (2006).
41. Martin-Villar E, Scholl FG, Gamallo C et al. Characterization of human PA2.26 antigen (T1a-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int. J. Cancer 113(6), 899-910 (2005).
42. Mishima K, Kato Y, Kaneko MK et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol. 111(6), 563-568 (2006).
43. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 111(5), 483-488 (2006).
44. Rahadiani N, Ikeda J, Makino T et al. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann. Surg. Oncol. 17(5), 1311-1323 (2010).
45. Suzuki H, Kato Y, Kaneko MK, Okita Y, Narimatsu H, Kato M. Induction of podoplanin by transforming growth factor-b in human fibrosarcoma. FEBS Lett. 582(2), 341-345 (2008).
46. Vormittag L, Thurnher D, Geleff S et al. Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio(chemo)therapy. Int. J. Radiat. Oncol. Biol. Phys. 73(3), 913-918 (2009).
47. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br. J. Cancer 96(1), 1-5 (2007).
48. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9(4), 261-272 (2006).
49. Kato Y, Kaneko MK, Kunita A et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci. 99(1), 54-61 (2008).
50. Kunita A, Kashima TG, Morishita Y et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am. J. Pathol. 170(4), 1337-1347 (2007).
51. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J. Clin. Oncol. 26(3), 354-360 (2008).
52. Kawase A, Ishii G, Nagai K et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int. J. Cancer 123(5), 1053-1059 (2008).
53. Kato Y, Vaidyanathan G, Kaneko MK et al. Evaluation of anti podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl. Med. Biol. 37(7), 785-794 (2010).
54. Patel SJ, Shapiro WR, Laske DW et al. Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 56(6), 1243-1252; discussion 1252-1243 (2005).
55. Reardon DA, Akabani G, Coleman RE et al. Phase II trial of murine 131I labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20(5), 1389-1397 (2002).
56. Bourdon MA, Coleman RE, Blasberg RG, Groothuis DR, Bigner DD. Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. Anticancer Res. 4(3), 133-140 (1984).
57. Reardon DA, Akabani G, Coleman RE et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. 24(1), 115-122 (2006).
58. Reardon DA, Quinn JA, Akabani G et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. J. Nucl. Med. 47(6), 912-918 (2006).
59. Boskovitz A, Akabani GH, Pegram CN, Bigner DD, Zalutsky MR. Human/murine chimeric 81C6 F(ab́)2 fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. Nucl. Med. Biol. 31(3), 345-355 (2004).
60. Akabani G, Reardon DA, Coleman RE et al. Dosimetry and radiographic analysis of 131I labeled anti tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a Phase II study. J. Nucl. Med. 46(6), 1042-1051 (2005).
61. Cokgor I, Reardon DA, Zalutsky MR et al. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 18(22), 3862-3872 (2000).
62. Akabani G, Reardon DA, Coleman RE et al. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a Phase II study. J. Nucl. Med. 46(6), 1042-1051 (2005).
63. Reardon DA, Zalutsky MR, Akabani G et al. A pilot study: 131I antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro. Oncol. 10(2), 182-189 (2008).
64. Zalutsky MR, Garg PK, Friedman HS, Bigner DD. Labeling monoclonal antibodies and F(ab́)2 fragments with the a-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl Acad. Sci. USA 86(18), 7149-7153 (1989).
65. Zalutsky MR, Reardon DA, Akabani G et al. Clinical experience with a-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nucl. Med. 49(1), 30-38 (2008).
66. Bartolomei M, Mazzetta C, Handkiewicz-Junak D et al. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide. Q. J. Nucl. Med. Mol. Imaging 48(3), 220-228 (2004).
67. Paganelli G, Bartolomei M, Ferrari M et al. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16(3), 227-235 (2001).
68. Riva P, Franceschi G, Frattarelli M et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a Phase I study. Clin. Cancer Res. 5(Suppl. 10), S3275-S3280 (1999).
69. Riva P, Franceschi G, Frattarelli M et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-Phase I and II study. Acta Oncol. 38(3), 351-359 (1999).
70. Riva P, Milani N, Gandolfi P, Larizza L. A 12-bp deletion (7818del12) in the c-kit protooncogene in a large Italian kindred with piebaldism. Hum. Mutat. 6(4), 343-345 (1995).
71. Larson SM. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. J. Natl Cancer Inst. 83(22), 1602-1604 (1991).
72. Goetz C, Riva P, Poepperl G et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J. Neurooncol. 62(3), 321-328 (2003).
73. De Santis R, Albertoni C, Petronzelli F et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin. Cancer Res. 12(7 Pt 1), 2191-2196 (2006).
74. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin C. Clin. Cancer Res. 12(10), 3200-3208 (2006).
75. Sundberg AL, Steffen AC. Enhancing the effect of radionuclide tumor targeting, using lysosomotropic weak bases. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 279-287 (2007).
76. Casaco A, Lopez G, Garcia I et al. Phase I single-dose study of intracavitary-administered nimotuzumab labeled with 188Re in adult recurrent high-grade glioma. Cancer Biol. Ther. 7(3), 333-339 (2008).
77. Sunada H, Magun BE, Mendelsohn J, Macleod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl Acad. Sci. USA 83(11), 3825-3829 (1986).
78. Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 972-975 (2004).
79. Rodeck U, Herlyn M, Herlyn D et al. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res. 47(14), 3692-3696 (1987).
80. Rodeck U, Herlyn M, Koprowski H. Interactions between growth factor receptors and corresponding monoclonal antibodies in human tumors. J. Cell Biochem. 35(4), 315-320 (1987).
81. Bender H, Takahashi H, Adachi K et al. Immunotherapy of human glioma xenografts with unlabeled, 131I, or 125I labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res. 52(1), 121-126 (1992).
82. Li L, Quang TS, Gracely EJ et al. A Phase II study of anti epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J. Neurosurg. 113(2), 192-198 (2010).
83. Rosenkranz AA, Vaidyanathan G, Pozzi OR, Lunin VG, Zalutsky MR, Sobolev AS. Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to a-particle emitting 211At. Int. J. Radiat. Oncol. Biol. Phys. 72(1), 193-200 (2008).
84. Foulon CF, Reist CJ, Bigner DD, Zalutsky MR. Radioiodination via d-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti epidermal growth factor receptor variant III monoclonal antibody. Cancer Res. 60(16), 4453-4460 (2000).
85. Harris TD, Kalogeropoulos S, Nguyen T et al. Design, synthesis, and evaluation of radiolabeled integrin avb3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother. Radiopharm. 18(4), 627-641 (2003).
86. Ramos OH, Kauskot A, Cominetti MR et al. A novel avb3-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin. Exp. Metastasis 25(1), 53-64 (2008).
87. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59(6), 1304-1312; discussion 1312 (2006).
88. Gutheil JC, Campbell TN, Pierce PR et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin avb3. Clin. Cancer Res. 6(8), 3056-3061 (2000).
89. Saga T, Sakahara H, Nakamoto Y et al. Radioimmunotherapy of human glioma xenografts in nude mice by indium-111 labelled internalising monoclonal antibody. Eur. J. Cancer 35(8), 1281-1285 (1999).
90. Debinski W, Thompson JP. Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas. Clin. Cancer Res. 5(Suppl. 10), S3143-S3147 (1999).
91. ClinicalTrials.gov. http://clinicaltrials.gov